Drug Profile
Asunaprevir - Bristol-Myers Squibb
Alternative Names: BMS-650032; SunvepraLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Antivirals; Carbamates; Cyclopropanes; Isoquinolines; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for Hepatitis C (Combination therapy, Treatment-experienced) in South Korea (PO)
- 29 Nov 2022 No development reported - Phase-III for Hepatitis C (Combination therapy, Treatment-experienced) in Taiwan (PO)
- 29 Nov 2022 No development reported - Phase-III for Hepatitis C (Combination therapy, Treatment-naive) in Spain, New Zealand, Italy, Ireland, France, Germany, Taiwan, South Korea, Russia, Poland, Netherlands, Israel, Austria, Argentina (PO) (NCT01581203)